The Clinical Investigations Support Office (CISC) is a centralized organization of individuals with specific and specialized roles and a protocol and data management system that provides essential support for investigational trials at the USC/Norris Comprehensive Cancer Center. This centralized administration of clinical research activities is critical to the efficient conduct of clinical trials at the various clinical sites of the Cancer Center. CISC provides the Cancer Center's clinical investigators access to services, technologies and scientific consultation to foster interaction and enhance scientific productivity. CISO provides a centralized administration for protocol development, review, regulatory compliance, study conduct and monitoring, and quality assurance. This shared resource has two components: a centralized Protocol Administration Unit and a Research Nursing/Data Management Unit. The Protocol Administration Unit provides the centralized support services necessary for the conduct of externally-funded and internally peerreviewed and monitored research clinical trials. The Research Nursing/Data Management Unit provides the centralized function of advising and assisting investigators in patient eligibility assessments, data quality control and oversight. The Cancer Center has provided a suite of offices located on the 7th floor of the Topping Tower with other offices for staff located throughout the hospital due to growth of clinical research. Satellite offices are located in close proximity to patient care areas at the Los Angeles County + USC Medical Center. CISO has important interactions and coordination of functions with the Biostatistics Core Resource, the Cancer Research Informatics Core (CRIC), and the protocol review and monitoring system (Clinical Investigations and Quality Assurance committees) which provide scientific peer review and quality assurance monitoring of the Center's clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-35
Application #
8056493
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
35
Fiscal Year
2010
Total Cost
$703,609
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications